絞り込み

16638

広告

Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.

著者 Thase ME , Youakim JM , Skuban A , Hobart M , Zhang P , McQuade RD , Nyilas M , Carson WH , Sanchez R , Eriksson H
J Clin Psychiatry.2015 Aug 4 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (29view , 0users)

Full Text Sources

Medical

To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs.
PMID: 26301771 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード